Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, is widely used to treat diabetes. However, its effect on pulmonary arterial hypertension (PAH) is unknown. In this study, we investigated its effects on rats with monocrotaline (MCT)-induced PAH and mechanisms on rat pulmonary artery smooth muscle cells (PASMCs). Liraglutide was investigated for both prevention and treatment of MCT-induced PAH. The hemodynamic and body weight changes, right heart hypertrophy, lung morphology, immune-reactivity of endothelial nitric oxide synthase (eNOS), endothelin-1 and cyclic guanosine monophosphate (cGMP) levels, protein expressions of eNOS, soluble guanylyl cyclase (sGCα), protein kinase G (PKG) and Rho kinase (ROCK) II pathway were measured in both in vivo and in vitro. Cell migration and cell cycle were also determined. Liraglutide both prevented and reversed MCT-induced PAH, right ventricle hypertrophy and pulmonary vascular wall remodeling. Protein expression of ROCK II was increased while eNOS, sGC and PKG were decreased. Pretreatment with liraglutide inhibited platelet-derived growth factor (PDGF)-BB stimulated PASMCs migration, which were associated with cell-cycle arrest at G0/G1 phase. Liraglutide may have both preventive and therapeutic effects on MCT-induced PAH, through the eNOS/sGC/PKG and Rho kinase pathways. Thus, liraglutide may have a therapeutic role in pulmonary vascular remodelling.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007506 | PMC |
| http://dx.doi.org/10.1038/srep31788 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Melatonin improves adverse vascular remodelling and redox homeostasis in monocrotaline-induced pulmonary arterial hypertension.
Arch Physiol Biochem
January 2025
Laboratório de Fisiologia Cardiovascular, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
This study explored the effects of melatonin on cardiac and vascular function, and redox homeostasis in model PAH. Male Wistar rats were divided into: control (CTR), monocrotaline [MCT (60 mg/kg, single dose i.p)], monocrotaline + sildenafil [MCT + SIL (50 mg/kg/day)], and monocrotaline + melatonin [MCT + MEL (10 mg/kg/day)].
View Article and Find Full Text PDFCombined exercise hinders the progression of pulmonary and right heart harmful remodeling in monocrotaline-induced pulmonary arterial hypertension.
J Appl Physiol (1985)
January 2025
Department of Physical Education, Laboratory of Exercise Biology, Federal University of Viçosa, Viçosa, Brazil.
Article Synopsis
- The study investigated whether combined moderate-intensity exercise could slow down harmful changes in the lungs and right heart in rats with pulmonary arterial hypertension (PAH) induced by monocrotaline (MCT).
- Rats underwent a 3-week exercise program including aerobic and resistance training, which improved their physical endurance and prevented negative changes in pulmonary artery resistance and right ventricular function.
- The exercise also helped maintain heart cell function, reduced structural damage to the right ventricle and lungs, and lowered oxidative stress levels associated with PAH.
Isorhamnetin alleviates symptoms and inhibits oxidative stress levels in rats with pulmonary arterial hypertension.
Iran J Basic Med Sci
January 2024
Department of Pharmacology, College of Pharmacy, Ningxia Medical University, Yinchuan, China.
Article Synopsis
- This study investigates the effects of isorhamnetin (ISO), a flavonoid from sea buckthorn, on pulmonary arterial hypertension (PAH) in rats, focusing on its potential to protect against the disease's severe effects.
- Ninety-five rats were used, with some receiving ISO treatment after being induced with PAH through monocrotaline, leading to significant improvements in lung function and structural changes.
- The findings suggest that ISO may work by regulating the p-c-src/NOX1 signaling pathway, enhancing antioxidant activity, and reducing harmful protein expressions associated with PAH.
[Mechanism of vitamin D deficiency involvement in the development of pulmonary arterial hypertension related to monocrotaline-induced connective tissue disease in rats].
Zhonghua Yi Xue Za Zhi
November 2024
Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing210008, China.
To investigating the impact of vitamin D (VitD) deficiency on the jagged 1 protein (Jagged1)/Notch3 signaling pathway in the pulmonary arteries of rats with monocrotaline (MCT)-induced connective tissue disease (CTD)-related pulmonary arterial hypertension (PAH) and to explore the pathological and molecular mechanisms of VitD involvement in the development of CTD-PAH. Twenty-four 7-week-old male Wistar rats were divided into a normal diet group and a VitD-free diet group using random number table, with 12 rats in each group. After 5 weeks of feeding, the rats were further randomly divided into saline and MCT groups, forming group A (normal diet+saline), group B (normal diet+MCT), group C (VitD-free+saline), and group D (VitD-free+MCT), with 6 rats in each group, and the rats were continued to be fed for another 4 weeks.
View Article and Find Full Text PDFPI3K p85α/HIF-1α accelerates the development of pulmonary arterial hypertension by regulating fatty acid uptake and mitophagy.
Mol Med
November 2024
Cardiovascular Department, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Background: Pulmonary arterial hypertension (PAH) is characterized by lipid accumulation and mitochondrial dysfunction. This study was designed to investigate the effects of hypoxia-inducible factor-1α (HIF-1α) on fatty acid uptake and mitophagy in PAH.
Methods: Peripheral blood samples were obtained from PAH patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!